// App-Quantinova.ai

e17033 : Compassionate use study of TRC105 (Endoglin Antibody) in combination with bevacizumab (Bev) in patients (pts) with refractory and metastatic choriocarcinoma.

Researchers

Presenter

  • Neil S. Horowitz

Principal Investigators

  • Kevin Meyer Elias

  • Donald Goldstein

  • Stephanie Morrissey

  • Siobhan A Collins

  • Julie Childress

  • Michael Seckl

  • Ross Stuart Berkowitz

Medical Centers

  • Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA

  • Brigham and Women's Hospital, Brookline, MA

  • Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA

  • Dana-Farber Cancer Institute, Boston, MA

  • Charing Cross Hospital, London, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Choriocarcinoma

Biomarkers

  • N/A

Drug/Treatment

  • Bevacizumab

  • TRC105

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved